TEL AVIV, ISRAEL, February 13, 2006 – Compugen Ltd. (NASDAQ: CGEN) announced today that Martin Gerstel, Chairman of the Board, is scheduled to present at the upcoming BIO CEO & Investor Conference 2006 at 3:00 PM (Eastern Time) on Wednesday, February 15, 2006 at the Waldorf Astoria Hotel in New York City.
A live Webcast of the presentation will be available on the Compugen Website at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CGEN&item_id=1210783
A replay will be available one hour after the presentation ends and will be accessible for one year following the presentation.
Compugen is a biotechnology discovery company focused on therapeutic and diagnostic products. The Company’s powerful predictive models and discovery engines enable the discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company’s pioneering and on-going incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen’s discovery efforts have focused mainly on cancer, cardiovascular and immune-related diseases. Product development is pursued both in-house and through collaborative arrangements. The Company’s primary business goal is to out-license therapeutic and diagnostic product candidates for commercialization by leading companies under milestone and revenue sharing agreements. Compugen has established an agricultural biotechnology affiliate – Evogene, and a small-molecule drug discovery affiliate – Keddem Bioscience. For additional information, please visit Compugen’s corporate Website at www.cgen.com.